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Introduction
Myocardial infarction (MI) is a major threat to human health and contributes to substantial morbidity and 
mortality worldwide (1, 2). Conventional treatments aim to promote reoxygenation of  the infarcted myocar-
dium, for example, through interventions, such as coronary artery bypass surgery or percutaneous coronary 
intervention, with the goal of  limiting infarct expansion and therefore progression to heart failure (3–5). 
While a regenerative response is absent in the adult mammalian heart, recent studies have demonstrated 
that the neonatal mouse and human hearts possess substantial regenerative capacities (6–9). However, this 
so-called “regenerative window” closes rapidly after birth. Notably, new blood vessel growth by angiogenesis 
was identified as 1 of  the 5 hallmarks of  regeneration (10). Thus, the left ventricular (LV) apical resection 
model of  cardiac regeneration in the neonatal mouse heart showed that new blood vessel formation precedes 
cardiomyocyte repopulation of  the regenerating area (11). Accordingly, the neonatal mouse should be useful 
for identification of  key regulators of  neovascularization following MI and providing potential therapeutic 
targets to promote neovascularization and, therefore, cardiac repair following MI in the adult.
MicroRNAs (miRs) regulate many biological processes, including vascular development and angiogenesis 
(12), and an increasing number of miRs have been shown either to target specific genes involved in angiogenesis 
or to be modulated by proangiogenic or antiangiogenic stimuli, including miR-221/222, miR-126, and the miR-
17/92 cluster (13). Additionally, miR expression is known to be altered in the setting of MI (14), and some miRs, 
such as miR-590 and miR-199a, induce cardiac repair by promoting cell-cycle reentry of adult cardiomyocytes 
and inducing their proliferation (15). Furthermore, other miRs, such as those in the miR-15 family, are upregu-
Following myocardial infarction (MI), the adult heart has minimal regenerative potential. 
Conversely, the neonatal heart can undergo extensive regeneration, and neovascularization capacity 
was hypothesized to contribute to this difference. Here, we demonstrate the higher angiogenic 
potential of neonatal compared with adult mouse cardiac endothelial cells (MCECs) in vitro and 
use this difference to identify candidate microRNAs (miRs) regulating cardiac angiogenesis after 
MI. miR expression profiling revealed miR-96 and miR-183 upregulation in adult compared with 
neonatal MCECs. Their overexpression decreased the angiogenic potential of neonatal MCECs in 
vitro and prevented scar resolution and neovascularization in neonatal mice after MI. Inversely, 
their inhibition improved the angiogenic potential of adult MCECs, and miR-96/miR-183–KO 
mice had increased peri-infarct neovascularization. In silico analyses identified anillin (ANLN) 
as a direct target of miR-96 and miR-183. In agreement, Anln expression declined following their 
overexpression and increased after their inhibition in vitro. Moreover, ANLN expression inversely 
correlated with miR-96 expression and age in cardiac ECs of cardiovascular patients. In vivo, ANLN+ 
vessels were enriched in the peri-infarct area of miR-96/miR-183–KO mice. These findings identify 
miR-96 and miR-183 as regulators of neovascularization following MI and miR-regulated genes, 
such as anillin, as potential therapeutic targets for cardiovascular disease.
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lated in the neonatal mouse heart where they repress several cell-cycle genes and contribute to cell-cycle arrest, 
thus limiting cardiac regenerative capacity (16). Interestingly, inhibition of the miR-15 family at early stages 
of life increases cardiomyocytes proliferation and cardiac repair (7). However, the precise role and therapeutic 
potential of specific miRs in cardiac repair remains poorly investigated. Moreover, miRs are known to act as 
inhibitory regulators of gene expression by binding to complementary mRNA transcripts (17), and their target 
genes in the context of neovascularization after MI have not yet been identified.
Here we demonstrate that neonatal cardiac endothelial cells (ECs) have a greater proangiogenic poten-
tial than adult cardiac ECs. We further show that neonatal cardiac ECs have a specific miR signature that 
includes miR-96 and miR-183 as potentially novel therapeutic candidates, and we identify the cytoskeletal 
regulator anillin (ANLN) as a target of  both miR-96 and miR-183. These findings raise the possibility that 
miR-96/miR-183 and their targets induce a more neonatal-like phenotype in adult cardiac ECs that may be 
exploited therapeutically to improve postinfarction neovascularization.
Results
Neonatal and adult cardiac ECs possess different angiogenic phenotypes. To assess whether neonatal and adult 
mouse cardiac ECs (MCECs) have different angiogenic capacities, MCECs from C57BL/6N mice aged P1 
(within the regenerative window — herein referred to as neonatal MCECs) and 4 weeks (after the regener-
ative window — herein referred to as adult MCECs) were used. As shown in Figure 1A, neonatal MCECs 
had higher cell-cell contact and enhanced cell-surface adhesion in comparison with adult MCECs, as 
assessed with the electric cell-substrate impedance sensing (ECIS) system. Compared with adult MCECs, 
neonatal MCECs also had an accelerated migration rate, as evaluated with the ECIS-based automated cell 
migration assay (Figure 1B), and a higher proliferation rate in culture, measured as 5-ethynyl-2′-deoxy-
uridine (EdU) incorporation (Figure 1C). When seeded at a high density (2 × 104 cells/cm2), both adult 
and neonatal MCECs form appropriate tube-like structures after 6 hours in culture (Figure 1D). However, 
neonatal but not adult MCECs formed extensive tube-like structures after 24 hours in culture when seeded 
at a lower density (1 × 104 cells/cm2) (Figure 1E). Taken together, these data indicate that neonatal cardiac 
ECs possess greater angiogenic potential than adult cardiac ECs.
The miR signature is different in neonatal and adult MCECs. The greater angiogenic potential of  neona-
tal versus adult MCECs may be the result of  several factors. For example, recent findings demonstrate 
that miRs regulate cardiovascular development, regeneration, and angiogenesis (12, 18). We, therefore, 
investigated whether a change in miR expression might regulate the angiogenic switch from neonatal to 
adult cardiac ECs. Expression profiling of  150 miRs in neonatal (P1) and adult (W4) MCECs (Figure 
2A) showed that all members of  the miR-183 cluster, comprising miR-96-5p, miR-182-5p, and miR-
183-5p, were upregulated in adult MCECs compared with neonatal MCECs (Figure 2B). In agreement 
with this finding, miR-183 and miR-96 are highly enriched in ECs according to the FANTOM5 miRNA 
Atlas (19). Interestingly, the expression of  these miRs in primary MCECs (CD31+/CD45–) collected 
within (P1), at the end (P7), and after (P12 and 8 weeks) the regenerative window increased gradually 
over time (Supplemental Figure 1A; supplemental material available online with this article; https://doi.
org/10.1172/jci.insight.134888DS1). These findings raised the possibility that miR-183 and miR-96 are 
linked to the decreased angiogenic potential of  adult MCECs compared with neonatal MCECs.
Overexpression of  miR-96 and/or miR-183 reduces the angiogenic capacity of  neonatal MCECs in vitro. To under-
stand whether the miR-183 cluster regulates the angiogenic potential of  MCECs we manipulated the expres-
sion levels of  the miR-183 cluster in neonatal MCECs using synthetic oligonucleotides. While mimic-medi-
ated miR-183 cluster overexpression in neonatal MCECs did not affect their migration rate (Supplemental 
Figure 2A), it reduced their proliferation rate (Figure 2C and Supplemental Figure 2B) and prevented the 
formation of  capillary-like structures in Matrigel (Figure 2D and Supplemental Figure 2C). Overexpression 
of  the individual members of  the cluster showed that miR-96 and miR-183, but not miR-182, reduced the 
proliferative rate and the formation of  the tube-like structure of  neonatal MCECs (Figure 2, C and D). These 
findings suggest that miR-96 and miR-183 regulate the angiogenic potential of  MCECs.
Overexpression of  miR-96 and miR-183 impairs angiogenesis and scar resolution following MI in neonatal mice. 
We next used the neonatal mouse model of  MI to investigate the effect of  miR-96 and miR-183 overexpres-
sion in vivo. Following induction of  MI, miR-96 and miR-183 mimics were injected into the peri-infarct 
area. To confirm the feasibility of  miR mimic delivery into the neonatal mouse heart after MI, we initially 
injected a combination of  miR-96 and miR-183 mimics at a total dose of  200 pmol (20). However, the 
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survival of  pups at 24 hours was dramatically reduced after miR-96 and miR-183 injection compared with 
control mimic (Figure 3A). We, therefore, decreased the dose to 50 pmol, which did not compromise sur-
vival rates compared with the control group (Figure 3B).
At day 1 following MI, RT-qPCR revealed a significant increase in expression of  both miR-96 (Supple-
mental Figure 3A) and miR-183 (Supplemental Figure 3B) in freshly isolated MCECs between the miR-96/
miR-183 and control mimic-injected groups. Expression of  miR-183, but not miR-96, was also significantly 
increased in cardiomyocytes (Supplemental Figure 3). At 3 weeks after MI, mice injected with 50 pmol miR-
96/miR-183 had increased retention of  scar tissue within the LV wall compared with that in the control 
group (Figure 3, C and D). Notably, the retention of  scar tissue was associated with decreased vascularization 
around the fibrotic tissue (Figure 3, E and F). Together, these data indicate that overexpression of  miR-96 and 
miR-183 inhibits the angiogenic response and scar resolution in the neonatal mouse heart after MI.
miR-96 and miR-183 exert their vascular effect by targeting Anillin. To identify candidate target genes for 
repression by miR-96 and miR-183, we performed an in silico analysis of  3′ untranslated (UTR) mRNA 
and identified genes that are predicted to be targets of  both miRs. We identified as common candidate 
Figure 1. Morphological and functional differenc-
es between neonatal and adult MCECs. (A) Graphs 
showing increased cell-cell contacts and cell-surface 
adhesions of neonatal mouse cardiac endothelial cells 
(MCECs) compared with adult MCECs. (B) Represen-
tative impedance curve and quantification showing 
accelerated migration of neonatal MCECs (red) com-
pared with adult MCECs (black). (C). Representative 
microphotographs and bar graph showing the higher 
percentage of EdU-proliferating cells in neonatal 
versus adult MCECs after 24 hours in culture. EdU+ 
cells are shown in red and indicated by arrows, DAPI+ 
nuclei are shown in blue. (D) Matrigel experiment with 
MCECs seeded at high density (2 × 104) showing that 
adult MCECs are able to form tube-like structures at 
6 hours in culture properly and demonstrating that 
the length of tube-like structures formed by the same 
number of neonatal MCECs is higher. (E) Representa-
tive microphotographs and bar graph showing that, 
whereas 1 × 104 neonatal MCECs form proper tube-like 
structures at 24 hours, adult MCECs barely form tube-
like structure at the same time point. Scale bar: 50 
μm. n = 3 (B); n = 4/group (A, C, D, and E). *P < 0.05, 
**P < 0.01 vs. adult MCECs (Student’s t test). Data are 
shown as mean ± SEM.
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pathways for miR-96 and miR-183 the Hippo pathway, the PI3K/AKT/FOXO signaling pathway, and 
the regulation of  the actin cytoskeleton (Supplemental Figure 4). Among the target genes in this pathway, 
anillin was predicted as the direct target of  both miR-96 and miR-183 by bioinformatics platforms (Figure 
4A). A luciferase reporter gene assay in HEK293T cells confirmed that miR-96 and miR-183 bound to 
the 3′-UTR sequence of  ANLN, and binding was impaired by a mutation in a predicted binding site of  
the ANLN 3′-UTR (Figure 4B). Consistent with a role for miR-96 and miR-183 in targeting anillin, their 
overexpression decreased Anln mRNA levels in neonatal MCECs (Figure 4C). On the other hand, inhib-
iting miR-96 and miR-183 in adult MCECs increased the expression of  Anln (Figure 4D). Together, these 
findings identify that miR-96 and miR-183 regulate several proangiogenic pathways and identify anillin as 
one of  the direct targets of  miR-96 and miR-183.
Inhibiting the miR-183 cluster improves the angiogenic capacity of  adult MCECs. Since overexpression of  the 
miR-183 cluster was found to impair the angiogenic properties of  neonatal MCECs, we asked whether 
inhibition of  the miR-183 cluster on adult MCECs may have the reciprocal effect. Inhibiting all members 
of  the miR-183 cluster in adult MCECs improved their rates of  migration (Figure 5, A and B), proliferation 
(Figure 5C and Supplemental Figure 5A), and their ability to form capillary-like structures (Figure 5D and 
Supplemental Figure 5B). Moreover, inhibiting miR-96 and miR-183 improved adult MCEC proliferation 
and tube-like formation, whereas miR-182 inhibition did not affect these measures (Figure 5, C and D). 
Together, these findings confirm that miR-96 and miR-183 inhibit the angiogenic potential of  MCECs and 
suggest that their expression in adult MCECs impairs their regenerative capacity.
miR-96 and miR-183 inhibition induces neovascularization in the adult mouse after MI. To investigate whether 
miR-96 and miR-183 impair angiogenic properties of  adult MCECs after MI, we induced MI by perma-
nent occlusion of  the left anterior descending (LAD) coronary artery in adult miR-96/miR-183 global KO 
mice and WT littermates.
While cardiac function and fibrosis content were unchanged (Supplemental Table 1), both capillary 
and arteriole densities were increased in the peri-infarct of  miR-96/miR-183–KO mice compared with 
those in WT controls (Figure 6, A–C) at 2 weeks after MI.
Notably, the peri-infarct area of  miR-96/miR-183–KO mice showed an increased number of  vessels 
expressing the miR-96/miR-183 target ANLN when compared with that of  WT mice (Figure 6D). In 
Figure 2. Mimic-mediated overexpression of the miR-183 cluster reduces the angiogenic potential of neonatal MCECs. (A) Volcano plot of the 
significantly differentially regulated miRs in adult mouse cardiac endothelial cells (MCECs) compared with neonatal MCECs. (B) Real-time PCR 
showing upregulation of miR-96-5p, miR-182-5p, and miR-183-5p in cultured adult MCECs compared with neonatal MCECs. Cultured neonatal 
MCECs were transfected with miR-96, miR-182, or miR-183 (at 25 nM) or with a combination of all mimics of the miR183 cluster (miR-183C - all at 
25 nM) or control mimic(s). **P < 0.01 vs. adult (Student’s t test). (C) Bar graph showing that overexpression of the miR-183 cluster, miR-96 or miR-
183, in neonatal MCECs prevents the formation of tube-like structures. (D) Bar graph showing that the number of EdU+-proliferating cells decreases 
after overexpression of the miR-183 cluster, miR-96 or miR-183, in neonatal MCECs. n = 3/group (B and C); n = 4/group (D). *P < 0.05, **P < 0.01 vs. 
control mimic (1-way ANOVA with Bonferroni’s post hoc test). Data are shown as mean ± SEM.
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addition, Anln overexpression in adult MCECs in vitro increases the formation of  capillary-like struc-
tures (Figure 6E). This finding confirms that miR-96 and miR-183 could control the expression of  proan-
giogenic target genes in MCECs during MI.
The miR-183 cluster in human cardiac ECs. To determine whether the miR-183 cluster regulates gene expres-
Figure 3. Mimic-mediated overexpression of miR-96 and miR-183 prevents scar tissue resolution and neovascular-
ization of the neonatal mouse heart after MI. (A and B) Survival curves show that, whereas all neonatal mice injected 
with a combination of miR-96 and miR-183 mimics at the dose of 200 pmol died within 24 hours after MI and mimic 
injection (A), the mortality rate of mice injected with miR-96 and miR-183 mimics at the dose of 50 pmol was similar to 
that of control mimic-injected mice (B). Representative microphotographs (C) and bar graph (D) (n = 6 control mimic, n = 
8 miR-96/miR-183 mimic) showing differences in fibrosis deposition (in red, assessed by Picrosirius red staining) between 
neonatal infarcted hearts injected with either control mimics or miR-96 and miR-183 mimics. Scale bar: 1000 μm. Repre-
sentative microphotographs (E) and bar graph (F) (n = 4 control mimic, n = 6 miR-96/miR-183 mimic) showing the reduced 
capillary density in the heart of neonatal mice subjected to MI and injected with miR-96 and miR-183 mimics compared 
with control injected mice. Capillaries are stained with isolectin-B4 (green fluorescence), and arterioles are stained with 
isolectin-B4 (green fluorescence) and α-smooth muscle actin (red fluorescence). Scale bar: 250 μm (left); 50 μm (right). *P 
< 0.05 vs. control mimic (Student’s t test). Analyses were performed at 21 days after MI. Data are shown as mean ± SEM.
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sion in human cardiac ECs (HCECs), we isolated CD31+CD45– cells from cardiac biopsies of participants aged 
<1 year up to 61 years of age (Supplemental Table 2 and Supplemental Figure 6, A–D). While the expression 
of both miRs was low in HCECs from neonates and infants up to 1 year of age, it increased in HCECs from 
8- to 10-year-old children and remained elevated in HCECs isolated from adults (Figure 7A). In contrast, ANLN 
expression was higher in HCECs in children of up to 5 years of age and decreased with age (Figure 7A). Cor-
relation analysis showed a significant inverse correlation between levels of ANLN and miR-96 and the age of the 
patients (Pearson coefficient r = –0.6311, P = 0.0278). The expression of both miR-96 and miR-183, therefore, 
increased with age in primary HCECs, whereas the expression of their target ANLN decreased.
Next, we investigated whether manipulation of  miR-96 and miR-183 could also affect the regenerative 
potential of  HCECs. For this experiment, we obtained commercial HCECs from adult donors, termed 
human cardiac microvascular ECs (HCMECs) (see Methods). Whereas mimic-mediated overexpression of  
miR-96 and miR-183 in these cells reduced the formation of  capillary-like structures (Figure 7B and Sup-
plemental Figure 7A) and the proliferation rate (Figure 7C and Supplemental Figure 7B), dual miR-96 and 
miR-183 inhibition increased both parameters (Figure 7, D and E, and Supplemental Figure 7, C and D).
Together, these findings agree with those obtained for MCECs and suggest that the miR-96 and miR-
183 pathway is conserved between mice and humans. Manipulation of  these miRs may therefore be a 
suitable therapeutic target to improve the angiogenic potential of  cardiac ECs in humans after MI, although 
this will likely be in combination with other therapeutic approaches that modulate inflammation and stim-
ulate cardiomyocyte regeneration.
Discussion
While it has been clear that the angiogenic mechanisms occurring during embryonic and adult life are 
different (21), the cellular and molecular pathways controlling this switch are relatively poorly under-
stood. Embryonic and neonatal ECs possess a specific transcriptional profile (22), and it is becoming 
Figure 4. Anillin is a direct target of miR-96 and miR-183. (A) Prediction of anillin (ANLN) as a target gene of miR-96 
and miR-183 by TargetScan. (B) Luciferase assay for ANLN 3′-UTR (n = 3/group). Luciferase activity at 48 hours after 
cotransfection of HEK293T cells with both miR-96 and miR-183 or control mimics and ANLN 3′-UTR or ANLN 3′-UTR 
mutated (mut). Relative gene expression of Anln after miR-96 and miR-183 overexpression (C) or inhibition (D) in 
mouse cardiac endothelial cells (MCECs). (n = 4/group). **P < 0.01 vs. control mimic or anti-miR (Student’s t test). 
Data are shown as mean ± SEM.
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increasingly clear that life stage also influences their phenotype, with “younger” ECs generally thought 
to possess greater angiogenic capacity (23). Here, we first set out to characterize the phenotypic changes 
between neonatal and adult primary cardiac ECs.
We observed that neonatal MCECs presented with increased proliferation rates and enhanced migra-
tory capacities when compared with adult MCECs, which resulted in higher angiogenic properties.
miRs are inhibitory regulators of  gene expression, which are implicated in the regulation of  vascular 
development (24) and postnatal angiogenesis (25). An increasing number of  miRs have been shown to 
target specific genes involved in angiogenesis or to be modulated by either proangiogenic or antiangiogen-
ic stimuli (12). We, therefore, investigated whether the phenotypical switch between neonatal and adult 
MCECs correlates with changes in the expression of  miRs. Here, we have identified the miR-183 clus-
ter as a regulator of  this phenotypical switch. Indeed, overexpression of  those miRs in neonatal MCECs 
decreased their angiogenic capacities, giving them a phenotype like that of  adult MCECs. Importantly, we 
identified that miR-96 and miR-183 were the cause of  this effect, whereas the other member of  the family, 
miR-182, did not seem to influence MCECs phenotype.
Angiogenesis is 1 of  the 5 hallmarks of  cardiac regeneration in neonatal mice, alongside remusculariza-
tion, electromechanical stability, resolution of  fibrosis, and immunological balance (10). Indeed, angiogen-
esis preceded cardiomyocyte repopulation of  the regenerating area in an apical resection model of  cardiac 
regeneration (11). Understanding the mechanisms underpinning revascularization of  the neonatal heart 
in the context of  cardiac regeneration is therefore critical to the development of  new therapies to improve 
Figure 5. Inhibition of the miR-183 cluster improves the angiogenic potential of adult MCECs. (A) Graph showing 
that inhibition of the miR-183 cluster improves migration of adult mouse cardiac endothelial cells (MCECs, green line) 
compared with adult MCECs transfected with control mimic (black line). (B) Bar graph showing increased migration rate 
of adult MCECs after miR-183 cluster inhibition. (C) Bar graph showing increased tube-like structures formation in adult 
MCECs transfected with miR-183 cluster or miR-96 or miR-183 inhibitors. (D) Bar graph showing a higher number of EdU+ 
cells (increased proliferation) in adult MCECs after inhibition of the miR-183 cluster or miR-96 or miR-183. n = 3/group (C); 
n = 4/group (B and D). *P < 0.05, **P < 0.01 vs. control anti-miR (Student’s t test or 1-way ANOVA with Bonferroni’s post 
hoc test. Data are shown as mean ± SEM.
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repair after MI and hamper the progression to heart failure. We, therefore, sought to determine whether 
manipulation of  the miR-183 cluster could be used to modify outcome following MI in the neonatal mouse.
Intracardiac injection of  miR-96 and miR-183 following induction of  MI in neonatal mice resulted in 
their increased expression in MCECs, which was associated with a reduction of  capillary density. Together 
with our in vitro observations, these results suggest that miR-96 and miR-183 can manipulate the pheno-
type of  MCECs in vivo. A failure of  the neonatal heart to resorb scar tissue was also observed. While this 
may be secondary to the reduced capillary density, we cannot rule out that it may be resulting from miR-96 
and miR-183 overexpression in other cell types, e.g., cardiomyocytes. Hence, given the upregulation of  
miR-96/miR-183 in both ECs and cardiomyocytes after delivery, their specific relevance in the observed 
phenotype cannot be distinguished. Moreover, both EC and cardiomyocyte miR-96/miR-183 expression 
may well have a role in each cell type and in mediating a crosstalk between these cell types.
To investigate the therapeutic potential of  miR-96 and miR-183 further, we performed converse in 
vitro and in vivo experiments in adult mice. We observed that inhibiting both miRs improved the angio-
genic capacities of  adult MCECs in vitro, indicating that these miRs may play central roles in regulating 
the phenotypical switch between neonatal and adult MCECs. These observations were also recapitulated 
in HCECs, highlighting the translatability of  this pathway. Of  therapeutic importance, we were able to 
Figure 6. Inhibition of miR-96 and miR-183 increase neovascularization in the adult mouse after MI. (A) Bar graph 
showing the increased number of capillaries (n = 5/group) and (B) small arterioles (n = 6 WT, n = 7 miR-96/miR-183 KO) 
in the peri-infarct of miR-96/miR-183–KO mice at 14 days after MI. *P < 0.05 vs. WT (Student’s t test). (C) Repre-
sentative microphotographs showing capillaries (stained by isolectin-B4, green fluorescence) and arterioles (stained 
by isolectin-B4, green fluorescence, and α-smooth muscle actin, red fluorescence). Scale bar: 250 μm (left); 50 μm 
(right). (D) Bar graph and representative microphotographs showing the increased percentage of ANLN+ vessels in 
the peri-infarct of miR-96/miR-183–KO mice at 14 days after MI (n = 6/group). ECs are stained by isolectin-B4 (green 
fluorescence). ANLN, red fluorescence. Scale bar: 20 μm. *P < 0.05 vs. WT (Student’s t test). (E) Adult mouse cardiac 
endothelial cells (MCECs) were transduced with lentiviral vectors LV-EGFP or LV-ANLN-EGFP and seeded on Matrigel. 
Representative Matrigel assay images and quantification as total tubule length (n = 5/group). Scale bar: 100 μm. **P < 
0.01 vs. LV-EGFP (Student’s t test). Data are shown as mean ± SEM.
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show that a global KO of  the miR-183 cluster was associated with increased vascularization of  the peri-in-
farct zone following MI. However, this was not associated with improved function in our 2-week study. In 
line with this, there is a disconnect and delay between improved neovascularization and the subsequent 
improvement in cardiac function and scar formation, which happens later, in patients following MI (26).
To understand the full potential of  miR-183 cluster inhibition as a therapeutic target, future studies 
should look past 2 weeks after MI and focus on the progression to heart failure.
It has been proposed that stimulating angiogenesis may benefit cardiac repair (27). However, our obser-
vations show that stimulating angiogenesis is not sufficient to provide the desired functional improvement 
of  cardiac function, likely because other processes would have to be costimulated, including cardiomyocyte 
proliferation and maturation as well as a beneficial inflammatory environment.
Successful characterization of  miR activity relies on identifying the best miR targets matching the 
observed phenotype and disease (28). Using a bioinformatic approach and an in vitro and in vivo valida-
tion, we have identified anillin as the target of  miR-96 and miR-183. Anillin is an actin-binding protein that 
is highly conserved across multiple species and associated with the cell cycle and, specifically, the comple-
tion of  cytokinesis (29). To analyze the role of  cytokinesis during cardiac development and MI, Hesse et al. 
generated an ANLN-EGFP reporter mouse for the investigation of  ANLN in the cell-cycle dynamics in the 
heart (30), showing nuclear localization of  ANLN-EGFP during embryonic heart development. Anillin 
was found to act as a mitotic marker in pluripotent stem cells and, importantly, marked endoreduplication 
in myocardial injury (30). Moreover, anillin is also a bona fide marker for cardiomyocyte binucleation, 
enabling unequivocal discernment of  such events from cardiomyocyte division in vitro and in vivo (30).
Recently, transgenic mice expressing an ANLN-EGFP construct under the control of  the endotheli-
al-specific Flt-1 promoter have been generated for the monitoring of  EC proliferation and cytokinesis (31). 
ANLN-EGFP signals overlap mainly with the presence of  Ki67+/PECAM+ cells during vascular develop-
ment and show a decline in EC proliferation between E9.5 and E12.5, therefore supporting the importance 
of  anillin in EC proliferation during vessel development but also its possible role in regulating EC sprouting 
in miR-96/miR-183–KO mice after MI.
Figure 7. Effect of miR-183 cluster manipulation on HCECs. (A) 
Real-time qPCR showing an age-dependent increased expression 
of miR-96 and miR-183 and decreased expression of ANLN in 
human cardiac endothelial cells (HCECs) obtained from cardiac 
biopsies of participants. Commercially available human cardiac 
microvascular endothelial cells (HCMECs) from adult participants 
were used to test the effect of miR-183 cluster manipulation in 
human cardiac ECs. (B) Bar graph showing that overexpression 
of miR-96 and miR-183 prevents the formation of capillary-like 
structures and (C) reduces the percentage of EdU+ cells in 
HCMECs. On the other hand, inhibition of miR-96 and miR-183 
increases the length of tube-like structures (D) and promotes pro-
liferation (E) of cultured HCMECs. n = 4/group. *P < 0.05, **P < 
0.01 vs. control (Student’s t test). Data are shown as mean ± SEM.
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In addition, it is conceivable that Anln upregulation in miR-96/miR-183–KO mice might therefore also 
affect arterial smooth muscle cells (SMCs) and thus increase arterial density through its binding to F-actin 
and nonmuscle myosin (32). Specifically, the molecular interactions between F-actin and nonmuscle myosin 
II govern the contraction of  the cytoskeleton, which modulates cell shape, division, and migration in SMCs 
during arteriogenesis (33, 34) However, further experiments would be required to investigate this question.
These findings provide valuable insights into the basic biology underpinning angiogenesis in the neo-
natal infarcted heart and elucidate potentially novel and fundamentally critical molecular mechanisms that 
govern angiogenesis after MI during cardiac regeneration. Thereby, our findings highlight the importance 
and functional role of  the miR-183 cluster in EC biology in reestablishing a neonatal-like regenerative phe-
notype in adult cardiac ECs. Moreover, miR-96 and miR-183 represent putative therapeutic targets in MI.
Methods
MCECs. MCECs were either purchased from Cell Biologics or isolated in-house from postnatal C57BL/6N 
mice. In-house MCECs were obtained from pooled hearts of  mixed-sex C57BL/6N mice aged between 
P1 and 8 weeks. Briefly, hearts were enzymatically digested using a Neonatal Heart Dissociation Kit (30-
098-373, Miltenyi Biotec) in combination with the gentleMACS Dissociator (130-093-235, Miltenyi Bio-
tec) to obtain a single-cell suspension of  all cardiac cells. Cardiomyocytes and fibroblasts were removed 
using a 40-μm cell strainer. CD31+/CD45– ECs were then obtained using microbeads (CD31 Microbe-
ads, mouse: 130-097-418 Miltenyi Biotec; CD45 Microbeads, mouse: 130-052-301, Miltenyi Biotec) and 
the Miltenyi Biotec MACS sorting technology according to the manufacturer’s instructions. Immediately 
after isolation, cells were either cultured in Complete Mouse Endothelial Cell Medium with growth fac-
tors supplements (PeloBiotech) with 10% FBS or used from passage 2–5. Commercial MCECs from Cell 
Biologics (catalog C57–6024) were isolated from 1-day-old (P1) and 4-week-old C57BL6 mice (35, 36). 
Cells were from pooled hearts of  mixed-sex donors, cultured on gelatin-coated plates, and maintained in 
Complete Mouse Endothelial Cell Medium with growth factors supplements (PeloBiotech) with 5% FBS 
and used from passage 2–5, according to the manufacturer’s recommendations. MCECs were used for 
functional assays (as detailed below) and miR PCR arrays.
To analyze the miR-96 and miR-183 expression in MCECs and cardiomyocytes after miR-96/miR-183 
injection, the protocol described above was applied; however, cardiomyocytes were collected after ECs 
depletion and cultured in a 6-well plate with DMEM 10% FBS for 2 hours to allow fibroblasts to attach to 
the plate. Cardiomyocytes were then collected from the media by centrifugation.
HCECs. HCMECs were purchased from PromoCell. HCMECs were isolated from a healthy male par-
ticipant (49 years of  age) and were cultured in EGM-2 (EBM-2 added with growth factors and other sup-
plements, PromoCell) with 10% FBS and used between passage 2 and 4. Additionally, primary CD31+/
CD45– HCECs were obtained from Massimo Caputo, University of  Bristol (REC reference: 15/LO/1064; 
IRAS ID: 156551). Cardiac biopsies from the right ventricle of  patients undergoing surgery with a diagno-
sis of  Tetralogy of  Fallot/pulmonary atresia were collected, and HCECs were isolated using the Neonatal 
Heart Dissociation Kit and MACS technology (Miltenyi Biotec). Immunocytochemistry for the endotheli-
al markers von Willebrand factor and CD31 was performed to characterize HCECs in culture. Briefly, cells 
were fixed in 4% buffered paraformaldehyde and permeabilized with 0.1% Triton X-100 before incubation 
with primary antibody for CD31 (1:100; clone JC70A, GA610, Dako) and von Willebrand factor (1:100, 
GA527, Dako). Alexa Fluor–labeled secondary antibodies (1:1000, Molecular Probes/Invitrogen) were 
used to detect primary antibodies. Staining with DAPI (1:2000; Vector Laboratories Inc.) was used to iden-
tify nuclei. Images were obtained using an Axio Observer.Z1 microscope with Zen Blue software (Zeiss).
Cell transfection. MCECs and HCMECs were transfected with 25 nM miR-96, miR-182, and miR-183 
miRIDIAN mimics and inhibitors (or controls) (Dharmacon) using Lipofectamine 2000 Reagent (Invi-
trogen). Individual miR transfections were performed using 25 nM mimics or inhibitors; cotransfection 
experiments using 2 (miR-96 and miR-183) or 3 (miR-96, miR-182, and miR-183) miRs were performed 
using the total dose of  25 nM of  either mimics or inhibitors.
ECIS system. Commercial neonatal and adult MCECs were plated on the ECIS chip array (8W1E or 
8W10E) in order to assess cell-cell and cell-surface adhesion properties as well as their migration rate. Adhesion 
and migration were additionally evaluated in commercial neonatal MCECs transfected with miR-96 and miR-
183 mimics (and controls) and commercial adult MCECs after transfection with miR-96 and miR-183 inhibitors 
(and controls). The migration speed was calculated in μm/h, Rb, and α as reported in Giaever and Keese (37).
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EdU proliferation assay. Proliferation assay was performed on MCECs and HCMECs transfected with 
miR mimics, miR inhibitors, or controls using the Click-iT EdU Alexa Fluor 555 imaging kit (Thermo 
Fisher Scientific). At 48 hours after transfection, ECs (4 × 103 cells/well) were seeded in 96-well plates and 
incubated with EdU (10 μmol/l) for 24 hours. Cells were fixed with buffered 4% PFA (MilliporeSigma) 
in PBS for 15 minutes at room temperature and stained following the manufacturer’s instructions. Nuclei 
were stained with DAPI. Experiments were performed in triplicate. Cells were analyzed at a ×400 magnifi-
cation, and the percentage of  EdU+ cells was determined.
Matrigel assay. MCECs or HCMECs were seeded in 6-well plates (1.5 × 104 cells/well); transfected with 
miR mimics, miR inhibitors, or controls for 48 hours; and then trypsinized and plated in a flat-bottomed 
96-well plate coated with growth factor–enriched Matrigel (Matrigel Matrix, Basement Membrane, BD 
Biosciences). On adult MCECs, Matrigel was also performed by seeding the cells at a density of  1 × 104 
cells/well. Endothelial network formation was quantified at 6, 12, and 24 hours in randomly captured 
microscopic fields (magnification ×40) by counting the length of  vascular-like structures.
RNA extraction miR expression profiling and analysis. Total RNA was extracted using the miReasy kit 
(QIAGEN). Real-time quantification to measure miRNA was performed with the TaqMan miRNA 
reverse transcription kit and miRNA assay (Thermo Fisher Scientific). miRNA expression was normal-
ized to the U6 small nucleolar RNA (snRU6). For mRNA analysis, cDNA was produced using the Quan-
tiTect Reverse transcription kit (QIAGEN). Expression was normalized to 18S ribosomal RNA. Real-time 
qPCR was used to measure the expression of  miR-96 (assay ID: 000186; Thermo Fisher Scientific), miR-
182 (assay ID: 000597, Thermo Fisher Scientific), miR-183 (assay ID: 002269; Thermo Fisher Scientific), 
and snRU6 (assay ID: 001973; Thermo Fisher Scientific). ANLN and 18S rRNA preoptimized primers 
were obtained from MilliporeSigma (KiCqStart Primers). miR expression profiling of  150 miRs was per-
formed using mouse miScript miRNA PCR arrays (96-well format; QIAGEN) and SYBR Green–based 
real-time PCR analysis, using the Roche LightCycler real-time PCR system. Relative expression was cal-
culated using the 2-ΔΔCt method (38). The web-based miScript miRNA PCR array data analysis tool was 
used to analyze the real-time PCR data (QIAGEN).
Animal work. C57BL/6N mice bred in-house from stock originally obtained from Harlan and aged 
between P1 and 10 weeks. miR-96/miR-183–KO mice (Mirc40; EMMA ID EM:10856; international 
strain designation C57BL/6N-Atm1Brd Mirc40tm1Hmpr/WtsiOulu) were obtained from the University of  Oulu 
(Finland) European Mouse Mutant Archive (EMMA).
Neonatal and adult mouse models of  MI. Female miR-96/miR-183–KO mice and C57BL/6N (controls) 
aged 8–10 weeks were used for adult MI studies. MI in adult mice was induced as previously described (39). 
Briefly, anesthetized mice (isoflurane) were orally intubated and artificially ventilated using a Minivent 
mouse ventilator (Harvard Apparatus). The chest was opened through an incision in the intercostal space 
and MI was induced by permanent ligation of  the proximal LAD coronary artery by using a 7.0 Mersilene 
suture (Ethicon). The surgical wound was sutured, and animals were allowed to recover.
Both male and female C57BL/6N mice aged P1 were used for neonatal MI studies. MI was induced by liga-
tion of the LAD coronary artery in P1 mice as described in refs. 8, 40. Briefly, anesthesia was induced by a com-
bination of hypothermia and breathable (isoflurane) anesthetic. The animal was secured onto an ice pack for the 
duration of the procedure to maintain adequate anesthesia. A 5-mm skin incision was placed over the left thorax 
above the fifth rib, the skin was blunt dissected, and a small opening was created at the fifth intercostal space to 
visualize the left pulmonary lobes and heart. The LAD was identified and ligated (9-0 Ethilon, Ethicon). Using a 
32-gauge insulin syringe, 200 pmol or 50 pmol of either miR mimics or control (total volume of 5 μL) was inject-
ed within the LV wall below the ligation. The ribs, pectoral muscles, and skin were closed (8-0 Prolene, Ethicon). 
Analgesia was administrated with one drop of 1:50 bupivacaine (Marcaine Polyamp Steripack 0.25%) in saline 
onto the wound. The entire litter was tattooed for identification purposes and returned to the nest.
In vivo high-resolution ultrasound. Cardiac functional parameters of  adult mice were assessed at base-
line (1 day before induction of  MI) and at 2 weeks. Briefly, anesthesia was induced using isoflurane in 
medical O2 at concentrations of  2%–3%. Isoflurane was used for anesthesia maintenance at around 2%. 
Rectal temperature was monitored (36.5°C–38°C) with a Physitemp RET-3 probe. Thoracic hair was 
removed using commercially available electric shavers (Philips Hairclipper, HC9490/15) and depilatory 
cream (Veet Hair Removal Cream for sensitive skin). Conductive ultrasound gel (Parkers Lab) was then 
applied to each paw to record ECG signals. Prewarmed Aquasonic 100 ultrasound transmission gel was 
applied onto the abdomen avoiding bubble formation. Image acquisition was performed on a Visual-
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sonics Vevo 770 ultrasound biomicroscope. Cardiac function was assessed using standard parasternal 
long-axis images of  the LV in M-mode and ECG-gated kilohertz visualization B-mode. Functional mea-
surements were extracted using Vevo 770 software.
Histological evaluation in the mouse heart. Fresh heart samples were fixed in 10% formalin for 24 hours 
and subsequently placed in 70% ethanol for at least 24 hours before being embedded in paraffin. Paraf-
fin-embedded samples were cut into sequential 4-μm-thick sections on superfrost slides (VWR). Slides were 
deparaffinized and rehydrated. Histological analysis was performed on Picrosirius red–stained sections. 
Capillary and arteriole densities were determined using fluorescent microscopy on sections stained with 
Alexa Fluor 488–conjugated isolectin-B4 (1:100, I2141, Molecular Probes), Cy3-conjugated α-vascular 
smooth actin (1:200, C6198, MilliporeSigma), and Anillin (1:100, ab154337, Abcam).
Bioinformatics prediction and pathway analysis of  miR-183 cluster target genes. Computational prediction of  
miR-183 cluster target genes was done using a published algorithm (TargetScan 7.2; http://www.targetscan.
org). MirPath (http://snf-515788.vm.okeanos.grnet.gr/) was used to perform miRNA pathway analysis.
Luciferase assay. Luciferase assay has been performed as previously described (41). ANLN 3′-UTR vec-
tor was from the LightSwitch 3′-UTR Reporter GoClone Collection (Active Motif). Primers for 3′-UTR 
mutation at the position 110–116 are as follows: forward 5′-CGAAAGGGTTTaataattTATTCACTACGTA 
-3′ and reverse 5′- TACGTAGTGAATAaattattAAACCCTTTCG -3′, where lowercase letters represent the 
miR-96 and miR-183 mutated seed sequence. Mutation was performed using GeneArt mutagenesis system 
(Thermo Fisher Scientific). Luciferase constructs were transfected into HEK293T cells together with miR-
96 and miR-183 mimics or p-SV-β-gal control vector. Cells were cultured for 48 hours and assayed with the 
Luciferase and β-Galactosidase Reporter Assay Systems (Promega). Luciferase values were normalized to 
protein concentration and β-galactosidase activity.
Lentiviral vectors. Lentiviral vectors pLV: ANLN-EGFP and control pLV: EGFP were purchased from 
Cyagen. Production and purification of  lentiviral particles were performed at Edinburgh University Core 
facilities. Cardiac ECs were transduced with 10 MOI of  lentiviral particles in full media containing 8 μg/
mL polybrene overnight. Transduced cells were FACS sorted to have a selected population expressing 
ANLN-EGFP and EGFP as control.
Statistics. Statistical analysis was performed using GraphPad Prism 5 software. Data are expressed as 
mean ± SEM. Student’s unpaired 2-tailed t test was used for comparison of  2 groups. For comparison 
among more than 2 groups, a 1- or 2-way ANOVA with post hoc Bonferroni’s multiple comparison test was 
used. A P value of  less than 0.05 was interpreted to denote statistical significance.
Study approval. All animal experiments were approved by and performed in accordance with the Uni-
versity of  Edinburgh Animal Welfare and Ethical Review Body and the UK Home Office. Experimental 
procedures involving human participants were performed in accordance with the Declaration of  Helsinki 
and were approved by the responsible ethics committees (NHS Health Research Authority, Whitefriars, 
Lewins Mead, Bristol, United Kingdom). Research on clinical samples was performed in agreement with 
the Human Tissue Act. Written informed consent was received from participants before inclusion in the 
study (REC reference: 15/LO/1064; IRAS ID: 156551).
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